Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

CorMedix Inc. (CRMD)

Pharmaceutical Preparations

https://www.cormedix.com

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

300 CONNELL DRIVE, SUITE 4200
BERKELEY HEIGHTS, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/13/2010

Market Cap

265,728,216

Shares Outstanding

54,810,000

Weighted SO

54,812,042

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

TARS --.--%

LIAN --.--%

ALDX --.--%

TVTX --.--%

ETON --.--%

TVTX --.--%

ETON --.--%

PGEN --.--%

PGEN --.--%

Beta

1.5980

Last Div

0.0000

Range

2.57-7.0

Chg

0.0400

Avg Vol

534185

Mkt Cap

265728216

Exch

NASDAQ

Country

US

Phone

908 517 9500

DCF Diff

3.9792

DCF

0.8458

Div Yield

0.0000

P/S

239.3454

EV Multiple

-4.1618

P/FV

6.0323

Div Yield %

0.0000

P/E

-5.2451

PEG

0.2283

Payout

0.0000

Current Ratio

4.7874

Quick Ratio

4.4263

Cash Ratio

2.5686

DSO

232.2161

DIO

1021.2537

Op Cycle

1253.4697

DPO

851.5122

CCC

401.9575

Gross Margin

-0.2914

Op Margin

-52.3686

Pretax Margin

-49.0987

Net Margin

-47.8424

Eff Tax Rate

0.0253

ROA

-0.9201

ROE

-0.8250

ROCE

-1.2471

NI/EBT

0.9744

EBT/EBIT

0.9376

EBIT/Rev

-52.3686

Debt Ratio

7.5420

D/E

9.4276

LT Debt/Cap

0.9041

Total Debt/Cap

0.9041

Int Coverage

8.9085

CF/Debt

-0.1167

Equity Multi

1.2500

Rec Turnover

1.5718

Pay Turnover

0.4286

Inv Turnover

0.3574

FA Turnover

0.4470

Asset Turnover

0.0192

OCF/Share

-0.8815

FCF/Share

-0.8885

Cash/Share

0.7916

OCF/Sales

-45.7504

FCF/OCF

1.0079

CF Coverage

-0.1167

ST Coverage

-319.3006

CapEx Coverage

-126.2666

Div&CapEx Cov

-126.2666

P/BV

6.0323

P/B

6.0323

P/S

239.3454

P/E

-5.2451

P/FCF

-5.1904

P/OCF

-5.4849

P/CF

-5.4849

PEG

0.2283

P/S

239.3454

EV Multiple

-4.1618

P/FV

6.0323

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 15, 08:30 CorMedix Inc. Announces Appointment of Chief Legal Officer GlobeNewswire Inc. Dec 04, 08:30 CorMedix Inc. Announces Partnership With The Leapfrog Group GlobeNewswire Inc. Nov 15, 12:57 CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients The Motley Fool Nov 14, 19:45 CorMedix (CRMD) Q3 2023 Earnings Call Transcript The Motley Fool Nov 14, 19:45 CorMedix (CRMD) Q3 2023 Earnings Call Transcript The Motley Fool Nov 14, 19:45 CorMedix (CRMD) Q3 2023 Earnings Call Transcript GlobeNewswire Inc. Nov 02, 08:30 CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

Revenue Product Segmentation